



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#11

APPLICANT(S): YEDGAR, Saul et al. EXAMINER: O SULLIVAN, Peter G

SERIAL NO.: 09/756,765 GROUP ART UNIT: 1621

FILED: January 10, 2001 Attorney Docket No.: P-2507-US

FOR.: USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASE

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

AUG 01 2003

Sir:

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes Form PTO-1449:

1. ☒ listing documents including patents, publications, and other information for consideration by the Examiner, copies of which are included with this information disclosure statement;
2. ☐ listing documents including patents, publications and other information that have been previously cited or submitted to the Patent Office in prior application U.S. Serial No. _____, filed _____ which is properly identified and relied on for an earlier effective filing date under 35 U.S.C. 120 for consideration by the Examiner; however, in accordance with 37 C.F.R. 1.98(d), copies of such documents are not included in this information disclosure statement; and/or
3. ☐ listing other information for the Examiner's consideration which was cited in a communication from a foreign patent office in a counterpart foreign application, a copy of which is included with this information disclosure statement.

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the

listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

I) ☐ Within three (3) months of filing the subject Application or entry of the subject Application into the national stage or before mailing of the first Office Action on the merits of the subject Application or a request for continued examination thereof, whichever event occurs last pursuant to of 37 C.F.R §1.97 (b); or

II) ☒ After the period specified in (I) but before the mailing date of either a final Official Action under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311 whichever occurs first and;


1. ☐ the undersigned hereby states that each item of information listed on the Form PTO-1449 was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement or (ii) not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this information disclosure statement; or

2. ☒ the undersigned hereby authorizes the Patent Office to charge the fee in the amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.

- III) ☐ After the period in (I) and (II) but before the payment of the issue fee and,
1. The undersigned hereby states:
- a) ☐ that each item of information cited on the form PTO-1449 was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or
- b) ☐ that no items of information contained in Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
2. ☐ The undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted,


Mark S. Cohen
Attorney for Applicant(s)
Registration No. 42,425

Dated: 30 July 2003


Eitan, Pearl, Latzer & Cohen Zedek, LLP.
10 Rockefeller Plaza, Suite 1001
New York, New York 10020
Tel: (212) 632-3480
Fax: (212) 632-3490

INFORM STATEMENT
JUL 31 2003
JC1 (use as
Sheet 1

[illegible][illegible]

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

 <p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Applicant Number	09/756,765
		Filing Date	January 10, 2001
		First Named Inventor	YEDGAR, Saul
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	P-2507-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	Group V Phospholipase A ₂ -mediated Oleic Acid Mobilization in Lipopolysaccharide-stimulated P388D ₁ Macrophages; BALSINDE Jesus, BALBOA Maria A., YEDGAR Saul, and DENNIS Edward A., The Journal of Biological Chemistry, Vol 275, Feb 18 pp4783-4786	<input type="checkbox"/>
	AE	Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane BECK, G. Ch, YARD B.A. SCHULTE J., OBERACKER, R., VAN ACKERN K, VAN DER WOUDE F.J, KRIMSKY M, KASZKIN M and YEDGAR Y.; British Journal of Pharmacology (2002) 135, 1665-1674	<input type="checkbox"/>
	AF	Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A ₂ ; CHEM, W.M, SORIA J, CORIA C, KRIMSKY M and YEDGAR S.; FEBS 26215 letters 522 (2002) 113-118	<input type="checkbox"/>
	AG	Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation; SCHNITZER Edit, DAGAN Arie, KRIMSKY Miron, LICHTENBERG Dov, PINCHUK Ilya, SHINAR Hadassa, YEDGAR Saul; CPL 104 (2000) 149-160	<input type="checkbox"/>
	AH	Inhibition of phospholipase A ₂ as a therapeutic target; YEDGAR Saul, LICHTENBERG Dov, SCHNITZER Edit, BBA Biochimica et Biophysica Acta 1488 (2000) 182-187	<input type="checkbox"/>
	AI	Modulation of IFN-GAMMA-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid; YARD Benito A., YEDGAR Saul, SCHEELE Martin, VAN DER WOUDE Diane, BECK Grietje, HEIDRICH Barbel, KRIMSKY Miron, VAN DER WOUDE Fokko J, and POST Stefan TRANSPLANTATION Vol 73, 984-992, No. 6, March 27, 2002	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

RECEIVED

AUG 01 2003

TECH CENTER 1600/2900

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.